Xintela looking for partners to reach patients faster, two main projects bring optimism

Xintela AB has reported positive results in its two main projects in regenerative medicine and cancer.

The company said on Friday that its  key technology platform Xinmark showed the quality, as well as its results-focused team.

The Swedish biomedical company said it will work on projects with confidence that this year will be eventful.

New results from a cancer project show that Xintelas targeting antibody kills glioblastoma cells both in cell studies and in an animal model. The company also noted progress made in the treatment of the brain tumor glioblastoma.

Related to that, Xintela has identified a suitable antibody and produced a so-called “Antibody-Drug Conjugate” (ADC), where a chemotherapy substance is linked to the antibody.

The work was conducted in collaboration with researchers from the Rudbeck Laboratory at Uppsala University. Additional studies are underway to finalize results for publication in an international scientific journal. We’ve asked the company which one it is, in an email.

Xintelas looking for partner to get revenues earlier

Xintelas said it looks for an industrial partner at an early stage to come to market and reach patients more rapidly and generate revenues earlier.

“These positive results confirm our treatment concept and give us the data we need to initiate discussions with potential partners for further development and commercialization of a product for the treatment of glioblastoma. We can now also initiate the work of applying for an orphan drug designation for the ADC therapy,” comments Xintelas CEO Evy Lundgren-Åkerlund.

Xintela said it was also analyzing tumor tissue samples to evaluate the possibility of developing a so-called Companion Diagnostic to show that the target molecule is expressed in the tumor. That way the patient can respond to the treatment Xintela is developing, says Evy Lundgren-Åkerlund.

Preparing Xintelas stem cells for clinical trials in horses and humans

Based on previous announcement of completing study in horses about its stem cells being safe on joints and bones certain damage, Xintela is preparing for a clinical study in horses with osteoarthritis, planned to start in the second half of 2017. Evidensia Equine Specialist Hospital in Helsingborg  will host the study.

“In order to start the clinical study on horses, we need to produce stem cells under GMP (Good Manufacturing Practice) and we expect to land a cooperation agreement for production shortly. We are also preparing to commercialize the stem cell product for horses,” says Evy Lundgren-Åkerlund.

Development for a stem cell product for the treatment of osteoarthritis in humans has progressed, and the company has already identified an orthopedic specialist clinic to conduct the clinical trial, planned for 2018. “We are now preparing for discussions with regulatory authorities for permission to start clinical studies,” says Evy Lundgren-Åkerlund.

Many of Xintelas milestones have already been met. The company has reported positive results in its two main projects in regenerative medicine and cancer. “This demonstrates the strength of our XINMARK(tm) technology platform and our results-focused team. I look forward to the continued development of the projects and I am confident that 2017 will be an eventful year for Xintela,” says Evy Lundgren- Åkerlund.